Form 4: Pfizer Director Cyrus Taraporevala Reports Acquisition of Phantom Stock Units

Director Cyrus Taraporevala reported the acquisition of phantom stock units representing deferred director's compensation.

Summary

• Cyrus Taraporevala, a director at Pfizer Inc., filed a Form 4 on April 2, 2025, reporting a transaction on March 31, 2025.
• The transaction involved the acquisition of 1,479.874 phantom stock units, representing deferred director's compensation.
• These units are settled in cash or common stock at the director's election following retirement from the Board of Directors.
• Following the reported transaction, Mr. Taraporevala beneficially owns 10,709.697 derivative securities.
• The filing also includes a power of attorney, granted on February 26, 2025, authorizing several individuals to act on Mr. Taraporevala's behalf for Section 16 filings.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan may incentivize continued service and commitment from the director.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to the market.

Comparison to Industry Standards

• Director compensation packages often include phantom stock units as a means of aligning executive incentives with shareholder value, a common practice among large publicly traded companies like Pfizer.
• Companies such as Johnson & Johnson and Merck also utilize similar deferred compensation strategies for their directors.

Stakeholder Impact

• Shareholders may view the phantom stock unit acquisition as a positive sign, aligning the director's interests with the company's long-term success.
• The compensation structure could incentivize the director to make decisions that benefit the company and its shareholders.

Key Dates

Keywords

Form 4, Pfizer, Director, Phantom Stock Units, Deferred Compensation, Beneficial Ownership, Cyrus Taraporevala